Stryker price target lowered to $380 from $395 at Truist

Truist lowered the firm’s price target on Stryker (SYK) to $380 from $395 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in MedTech. The firm expects Q1 performances to be in line or better than what feels like an anxious investor sentiment around Q1 volumes, the analyst tells investors in a research note. Truist adds that a premium valuation is justified for the stock given its view of the company’s high-quality, above-average revenue growth profile, though the firm also prefers to have higher conviction in EPS upside and faster earnings growth potential.